


## PHARMACEUTICAL 2022



## Unity Biotechnology Inc. Rank 323 of 466





## PHARMACEUTICAL 2022



## Unity Biotechnology Inc. Rank 323 of 466

The relative strengths and weaknesses of Unity Biotechnology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Unity Biotechnology Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Unity Biotechnology Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is 44%, being 34% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	90,504
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,617
Liabilities, Non-Current	48,526
Other Assets	24,266
Other Compr. Net Income	-49
Other Expenses	3,177
Other Liabilities	0
Other Net Income	-883
Other Revenues	4,784
Property and Equipment	9,942
Research and Development	38,393
Selling, General and Administrative Expense	23,056

Output Variable	Value in 1000 USD
Assets	124,712
Liabilities	65,143
Expenses	64,626
Revenues	4,784
Stockholders Equity	59,569
Net Income	-60,725
Comprehensive Net Income	-60,750
Economic Capital Ratio	44%

